Interesting:
https://www.fiercepharma.com/special-report/perjeta
This chart is handy:
- perjeta sales estimated to be USD $4.73B in 2022
- “The drug also set a precedent by becoming the first cancer drug approved by the FDA on the back of tumor shrinkage rather than survival data.”
- It’s approved for HER2-positive breast cancer ( about 10-15% of breast cancers )
https://www.grepmed.com/images/3513...agnosis-molecular-incidence-subtypes-invasive
The RAC 3-Pillar Trifecta, page-424
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |